Distribution of human papillomavirus types, cervical cancer screening history, and risk factors for infection in Manitoba

Chronic Diseases and Injuries in Canada

Volumn 32, Issue 4, 2012, Pages 177-185

  Demers, A A ^a,b,c   Shearer, B ^d   Severini, A ^e   Lotocki, R ^f,g   Kliewer, E V ^b,c,h   Stopera, S ⁱ   Wong, T ^a,j   Jayaraman, G ^a,j  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b CancerCare Manitoba ^*  (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d International Centre for Infectious Diseases   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f Gynecological Oncology   (Canada)

^g Manitoba Cervical Cancer Screening Program   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ Manitoba Health   (Canada)

^j UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

Early detection of cancer; Papillomavirus infections; Prevalence; Risk factors; Uterine cervical dysplasia

Indexed keywords

ADULT; AGE; AGED; ALPHAPAPILLOMAVIRUS; AMERICAN INDIAN; ARTICLE; CANADA; CONFIDENCE INTERVAL; EARLY DIAGNOSIS; ESKIMO; ETHNOLOGY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS INFECTION; PREVALENCE; QUESTIONNAIRE; RISK; RISK FACTOR; SEXUAL BEHAVIOR; STATISTICAL MODEL; STATISTICS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; AGE FACTORS; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONFIDENCE INTERVALS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INDIANS, NORTH AMERICAN; INUITS; LOGISTIC MODELS; MANITOBA; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84867720388     PISSN: 02288699     EISSN: 14818523     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24 Suppl 3:S178-S186.
2. Brisson M, van de Velde N, Boily M-C. Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect. 2011;87(1):41-43.
3. Smith MA, Canfell K, Brotherton JML, Lew J-B, Barnabas RV. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer. 2008;123(8):1854-1863.
4. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39-44.
5. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85(7):499-502.
6. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325-339.
7. Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex Health. 2010;7(3):376-382.
8. Kliewer EV, Demers AA, Brisson M, Severini A, Lotocki R, Elias B, et al. The Manitoba human papillomavirus vaccine surveillance and evaluation system. Health Rep. 2010;21(2):37-42.
9. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
10. Higuchi R. Simple and rapid preparation of samples for PCR. In: Erlich HA, editor. PCR Technology. Principles and Applications for DNA Amplification. New York: Stockton Press; 1989. p. 31-38.
11. Josefsson A, Magnusson P, Gyllensten U. Human papillomavirus detection by PCR and typing by Dot-Blot. In: Peeling RW, Sparling PF, editors. Sexually Transmitted Diseases. Methods and Protocols. Totowa (NJ): Humana Press; 1999. p. 171-193.
12. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
13. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 1995 Apr;76 (Pt 4):1057-1062.
14. Evander M, Edlund K, Bodén E, Gustafsson A, Jonsson M, Karlsson R, et al. Comparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol. 1992;30(4):987-992.
15. Strauss S, Jordens JZ, Desselberger U, Gray JJ. Single-tube real-time nested polymerase chain reaction for detecting human papillomavirus DNA. Diagn Mol Pathol. 2000;9(3):151-157.
16. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764-1772.
17. Zubach V, Smart G, Ratnam S, Severini A. Novel microsphere-based method for detection and typing of 46 mucosal human papillomavirus types. J Clin Microbiol. 2012;50(2):460-464.
18. Rebbapragada A, Perusini A, Di Prima A, Salit I, Goleski V, Severini A. Evaluation of test performance characteristics and operational parameters of 5 HPV genotyping assays. 26th International Papillomavirus Conference, Montreal, Canada, July 3-8: 2010.
19. de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27.
20. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-459.
21. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819.
22. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-1799.
23. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1157-1164.
24. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-632.
25. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24 Suppl 3:S3+78-89.
26. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007;97(1):129-132.
27. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(Supplement 3):S52-S61.
28. Moore RA, Ogilvie G, Fornika D, Moravan V, Brisson M, Amirabbasi-Beik M, et al. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women-implications for vaccination. Cancer Causes Control. 2009;20(8):1387-1396.
29. Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ. 2000;163(5):503-508.
30. Kurz J, Mitra K, Adam R, Miao X, MacKay JS, Isa NN, et al. PCR detection and typing of genital papillomavirus in a New Brunswick population. Int J Cancer. 1993;55(4):604-608.
31. Young TK, McNicol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women. Sex Transm Dis. 1997;24(5):293-298.
32. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl 1):S1-15.
33. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005;15(5):727-746.
34. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Supplement 3):S42-S51.
35. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009;12(5/6):291-307.
36. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226.
37. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428.
38. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23):2995-3002.
39. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 2008;68(21):8813-8824.
40. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis. 2002;186(4):462-469.
41. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168(4):421-425.
42. Decker K, Demers A, Chateau D, Musto G, Nugent Z, Lotocki R, et al. Papanicolaou test utilization and frequency of screening opportunities among women diagnosed with cervical cancer. Open Med. 2009;3(3):140-147.
43. Boulanger JC, Fauvet R, Urrutiaguer S, Drean Y, Sevestre H, Ganry O, et al. [Cytological history of cases of invasive cervical cancer diagnosed in France in 2006.] Gynecol Obstet Fertil. 2007;35(9):764-771.
44. van der Aa MA, Schutter EM, Looijen-Salamon M, Martens JE, Siesling S. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of The Netherlands, 1992-2001. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):204-209.
45. Priest P, Sadler L, Peters J, Crengle S, Bethwaite P, Medley G, et al. Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading. BJOG. 2007;114(4):398-407.
46. Depuydt CE, Arbyn M, Benoy IH, Vandepitte J, Vereecken AJ, Bogers JJ. Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection? J Cell Mol Med. 2009;13(9B):4051-4060.